ReviewOpen Access
Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis
Authors
Author Affiliations
First Affiliated Hospital of Xi'an Jiaotong University, Ministry of Education of the People's Republic of China, Precision for Medicine (United States), Xi'an Institute of Optics and Precision Mechanics, ...
Published InAnnals of Medicine
Year2021
Citations67
Abstract
OBJECTIVE: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the survival outcomes of urinary system cancers; however no agreement has been reached. This meta-analysis aimed to explore the prognostic significance of pre-treatment SII in tumours of the urinary system. METHODS: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to 30 August 2020. The hazard ratios (HRs) with 95% confidence intervals (CIs) were computed to estimate the associations of pre-treatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS) in urinary system cancers. RESULTS: < .001). CONCLUSIONS: Pre-treatment SII could be used as a non-invasive and promising biomarker to indicate the prognosis of urinary system cancer…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.